PMID- 34632870
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220307
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 20
DP  - 2021 Jan-Dec
TI  - Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced 
      Laryngeal Squamous Cell Carcinoma.
PG  - 15330338211046432
LID - 10.1177/15330338211046432 [doi]
LID - 15330338211046432
AB  - This study aimed to explore the effect of programmed death-ligand 1 (PD-L1) in 
      cancer-associated fibroblasts (CAFs) on advanced laryngeal squamous cell 
      carcinoma (LSCC). The expression of PD-L1 in advanced LSCC tumor tissues was 
      observed in 83 patients with LSCC by immunofluorescence microscopy and compared 
      with that in normal laryngeal mucosa. The CAFs of LSCC and normal fibroblasts 
      (NFs) were isolated, cultured, purified, and examined by fluorescence. The 
      expression of PD-L1 in purified CAFs and NFs was measured by flow cytometry. The 
      expression of PD-L1 in CAFs was downregulated through small interferring RNA 
      (siRNA) transfection. The proliferation and migration capacities of CAFs were 
      observed using proliferation and scratch tests, respectively. The proliferation 
      of HEP-2 cells and T cells was measured after cocultured with CAFs. The secretion 
      of interleukins IL-2 and IL-10 was detected using enzyme-linked immuno sorbent 
      assay (ELISA). PD-L1 was expressed in 62 of 83 cases of the advanced LSCC tumor 
      tissues. Also, CAFs expressed more PD-L1 compared with NFs. The proliferation and 
      migration capacities of CAFs were significantly lower after transfection with 
      PD-L1-siRNA. The proliferation rate of HEP-2 cells cocultured with CAFs decreased 
      in PD-L1-siRNA-transfected cells. However, the proliferation rate of T cells 
      increased in transfected cells. The ELISA results showed that the secretion of 
      IL-2 increased and that of IL-10 decreased in PD-L1-siRNA-transfected cells. The 
      expression of PD-L1 in CAFs of advanced LSCC was higher than that in NFs. The 
      downregulation of PD-L1 reduced the proliferation and migration of CAFs and HEP-2 
      cells but enhanced the proliferation and pro-inflammatory function of T cells in 
      the coculture experiment.
FAU - Yang, Zhendong
AU  - Yang Z
AD  - Department of Otolaryngology, 74566The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
AD  - Department of Otolaryngology, Suzhou Ninth Hospital affiliated to Soochow 
      University, Suzhou, China.
FAU - Wang, Jinxin
AU  - Wang J
AD  - Department of Otolaryngology, 74566The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Chen, Chun
AU  - Chen C
AD  - Department of Otolaryngology, 74566The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Sun, Peng
AU  - Sun P
AD  - Department of Otolaryngology, 74566The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
FAU - Yu, Yafeng
AU  - Yu Y
AUID- ORCID: 0000-0003-3558-0263
AD  - Department of Otolaryngology, 74566The First Affiliated Hospital of Soochow 
      University, Suzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Apoptosis
MH  - B7-H1 Antigen/genetics/*metabolism
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Cancer-Associated Fibroblasts/*pathology
MH  - Carcinoma, Squamous Cell/genetics/metabolism/*pathology
MH  - Case-Control Studies
MH  - Cell Cycle
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/genetics/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Survival Rate
MH  - Tumor Cells, Cultured
PMC - PMC8504221
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - cancer-associated fibroblast
OT  - immunosuppression
OT  - programmed death-ligand 1
OT  - proliferation
COIS- Declaration of Conflicting Interests: The authors declare that they have no 
      competing interests.
EDAT- 2021/10/12 06:00
MHDA- 2022/03/08 06:00
PMCR- 2021/10/09
CRDT- 2021/10/11 08:45
PHST- 2021/10/11 08:45 [entrez]
PHST- 2021/10/12 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2021/10/09 00:00 [pmc-release]
AID - 10.1177_15330338211046432 [pii]
AID - 10.1177/15330338211046432 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211046432. doi: 
      10.1177/15330338211046432.